DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for small intestine neoplasm — screening already-approved drugs against its 12-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSmall intestine neoplasm maps to a 12-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for small intestine neoplasm is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
nuclear receptor subfamily 1 group H member 3 (NR1H3) — NR1H3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5HJS · 1.72 Å · ligand 2-chloro-4-{1'-[(2R)-2-hydroxy-3-methyl-2-(trifluoromethyl)butanoyl]-4,4'-bipiperidin-1-yl}-N,N-dimethylbenzamide (668). Experimental structure, not a prediction.
What the evidence adds up to
Small intestine neoplasms are uncommon. A 1959 review notes that comprehensive studies had usually been derived from autopsy material, and relatively few papers had considered these tumours purely from a clinical perspective. Malignant tumours of the small intestine are rare, and most are adenocarcinomas. Primary squamous cell carcinoma of the small intestine is sporadic, with only a few cases reported in the literature.
A 2025 case report describes a 56-year-old woman with a history of exudate leakage for more than 40 years after an appendectomy. She presented with increasing leakage, abdominal pain, and fever, and was diagnosed with primary squamous cell carcinoma of the ileum after intestinal resection and fascial plasty. She declined adjuvant chemotherapy and died 9 months after diagnosis. The authors also reviewed 26 reported cases, summarising clinical features and treatments, and discussed potential pathogenesis and optional therapeutic strategies.
The 1959 paper provides no survival or response data. The 2025 case report offers a single patient outcome — death at 9 months — and a literature review of 26 cases, but no pooled survival statistics or response rates are given. No drug is mentioned in any abstract, and no treatment efficacy is reported.
What is missing is any prospective trial data, any systematic collection of outcomes across the 26 reviewed cases, and any patient stratification by tumour subtype or molecular profile. Without funding for a registry or a clinical trial, the evidence remains limited to case reports and historical autopsy series.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
New England Journal of Medicine · 1959 · 289 citations
Tumors of the Small Intestine
AbstractNEOPLASMS of the small intestine are uncommon. Although many individual case reports or studies of a specific tumor or tumor site have been published, comprehensive reviews have usually been derived, either partially or completely, from autopsy material. Relatively few papers have considered tumors of the small intestine purely from a clinical perspective.Though neoplasms of the small bowel were described in the literature as long ago as 1824, according to Pridgen, Mayo and Dockerty,1 little interest in this subject was apparent until the report of Rankin and Mayo2 appeared in 1930 and that of Raiford3 in 1932. In 1934 Sowles . . .
Frontiers in Oncology · 2025 · 2 citations · open access
Squamous cell carcinoma of the small intestine: a case report and review of literature
AbstractMalignant tumors derived from the small intestine are rare, and most are adenocarcinomas. Primary squamous cell carcinoma of the small intestine is sporadic with a few cases reported in the literature. This study reports a case of a 56-year-old female who had a history of leakage of exudate for more than 40 years after an appendectomy. The patient presented with increasing leakage of exudate, abdominal pain, and fever this time, and was diagnosed with primary squamous cell carcinoma of the ileal after an intestinal resection and a fascial plasty. The patient declined to receive adjuvant chemotherapeutic treatment and died 9 months after the diagnosis of the tumor. Additionally, we reviewed 26 reported cases, summarized the clinical features and treatments, and discussed the potential pathogenesis and optional therapeutic strategies for primary squamous cell carcinoma of the small intestine.
Image 1_Squamous cell carcinoma of the small intestine: a case report and review of literature.tif
AbstractMalignant tumors derived from the small intestine are rare, and most are adenocarcinomas. Primary squamous cell carcinoma of the small intestine is sporadic with a few cases reported in the literature. This study reports a case of a 56-year-old female who had a history of leakage of exudate for more than 40 years after an appendectomy. The patient presented with increasing leakage of exudate, abdominal pain, and fever this time, and was diagnosed with primary squamous cell carcinoma of the ileal after an intestinal resection and a fascial plasty. The patient declined to receive adjuvant chemotherapeutic treatment and died 9 months after the diagnosis of the tumor. Additionally, we reviewed 26 reported cases, summarized the clinical features and treatments, and discussed the potential pathogenesis and optional therapeutic strategies for primary squamous cell carcinoma of the small intestine.
Image 2_Squamous cell carcinoma of the small intestine: a case report and review of literature.tif
AbstractMalignant tumors derived from the small intestine are rare, and most are adenocarcinomas. Primary squamous cell carcinoma of the small intestine is sporadic with a few cases reported in the literature. This study reports a case of a 56-year-old female who had a history of leakage of exudate for more than 40 years after an appendectomy. The patient presented with increasing leakage of exudate, abdominal pain, and fever this time, and was diagnosed with primary squamous cell carcinoma of the ileal after an intestinal resection and a fascial plasty. The patient declined to receive adjuvant chemotherapeutic treatment and died 9 months after the diagnosis of the tumor. Additionally, we reviewed 26 reported cases, summarized the clinical features and treatments, and discussed the potential pathogenesis and optional therapeutic strategies for primary squamous cell carcinoma of the small intestine.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
